1985: Degree cum laude in Biological Sciences, University of Padova, Italy.
1991: Ph.D. in Molecular and Cellular Biology and Pathology, University of Padova, Dept. of Biological Chemistry, Padova, Italy.

Working Experiences
1991 - 1998: Graduated Technician at the Department of Biological Chemistry, University of Padova.
1998 - 2014: Assistant Professor (“Ricercatore universitario”) at the Department of Biomedical Sciences, University of Padova
2014 – present: Associate Professor at the Department of Biomedical Sciences, University of Padova

Abroad Experiences
1989: Short term EMBO fellowship, at the Friedrich Mieschner Institute, Basel, Switzerland.
1995: CNR-NATO fellowship, at the Harvard Medical School, Boston, USA.
1998: fellowship from the "Giovanni Armenise- Harvard Foundation for advanced scientific research", at the Harvard Medical School, Boston, USA.

Teaching Activity
1992 to present: classes of Chemistry and Biochemistry for different Courses of the Medical School, University of Padova.
2005 to present: member of the teaching staff of the PhD School in Biosciences and Biotechnology and of the PhD Program in Biomedical Sciences, University of Padova; supervisor of several PhD students.

She has been always involved in projects concerning protein phosphorylation and structural and functional characterization of protein kinases and phosphatases. Her present research is mainly focused on protein kinases involved in signal transduction and regulation of cell death/survival, and on developing of specific kinase inhibitors. She is author of >100 scientific papers published in international journals (H-index 43, Google Scholar), 5 chapters on scientific books, and several communications and posters at international meetings.

  1. Borgo C, D'Amore C, Sarno S, Salvi M, Ruzzene M. Protein kinase CK2: a potential therapeutic target for diverse human diseases. Signal Transduct Target Ther. 2021 May 17;6(1):183. doi: 10.1038/s41392-021-00567-7. PMID: 33994545; PMCID: PMC8126563.
  2. Zonta F, Borgo C, Quezada Meza CP, Masgras I, Rasola A, Salvi M, Pinna LA, Ruzzene M. Contribution of the CK2 Catalytic Isoforms α and α' to the Glycolytic Phenotype of Tumor Cells. Cells. 2021 Jan 18;10(1):181. doi: 10.3390/cells10010181. PMID: 33477590; PMCID: PMC7831337.
  3. Di Maira G, Gentilini A, Pastore M, Caligiuri A, Piombanti B, Raggi C, Rovida E, Lewinska M, Andersen JB, Borgo C, Salvi M, Ottaviani D, Ruzzene M, Marra F. The protein kinase CK2 contributes to the malignant phenotype of cholangiocarcinoma cells. Oncogenesis. 2019 Oct 22;8(11):61. doi:10.1038/s41389-019-0171-x. PubMed PMID: 31641101; PubMed Central PMCID: PMC6805921.
  4. Role of protein kinase CK2 in antitumor drug resistance. Borgo C, Ruzzene M. J Exp Clin Cancer Res. 2019 Jul 5;38(1):287. doi: 10.1186/s13046-019-1292-y
  5. Ottaviani D, Marin O, Arrigoni G, Franchin C, Vilardell J, Sandre M, Li W, Parfitt DA, Pinna LA, Cheetham ME, Ruzzene M. Protein kinase CK2 modulates HSJ1 function through phosphorylation of the UIM2 domain. Hum Mol Genet. 2017 Feb 1;26(3):611-623.

Full list of publications

University of Padova
MIUR (Italian Ministry of Education, Universities and Research)
AIRC (Italian Association for Cancer Research)